Complete Filing Data
Akari Therapeutics Plc reported Stockholders Equity of $28.33 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Akari Therapeutics Plc did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$17.3M | -$19.8M | -$10.0M | -$17.7M | -$17.4M | -$17.1M | -$16.8M | -$20.5M | -$35.4M | -$18.1M | -$45.3M | -$1.9M | -$3.6M | -$4.3M | -$2.1M | -$675.0K | -$1.0M | -$1.4M | -$3.1M | -$1.8M |
| Operating Income Loss | -$17.3M | -$21.6M | -$16.8M | -$23.1M | -$17.2M | -$18.0M | -$17.0M | -$20.8M | -$37.8M | -$27.2M | -$30.6M | -$1.9M | -$3.6M | -$3.7M | -$2.2M | |||||
| Selling General And Administrative Expense | $9.3M | $9.7M | $11.4M | $13.5M | $8.1M | $9.2M | $8.2M | $11.7M | $11.8M | $9.9M | $5.5M | $303.1K | $2.3M | $2.2M | $1.4M | |||||
| Research And Development Expense | $2.8M | $7.0M | $5.5M | $9.6M | $9.1M | $8.8M | $8.7M | $11.8M | $23.3M | $17.3M | $5.8M | $1.6M | $1.3M | $1.5M | $841.0K | |||||
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$44.0K | $302.0K | -$269.0K | -$230.0K | $107.1K | -$299.2K | $3.6K | -$116.2K | $43.9K | -$436.6K | $110.4K | $79.4K | ||||||||
| Comprehensive Income Net Of Tax | -$17.3M | -$19.5M | -$10.3M | -$18.0M | -$17.3M | -$17.4M | -$16.8M | -$20.6M | -$35.4M | -$18.6M | -$45.2M | -$1.9M | ||||||||
| Nonoperating Income Expense | -$1.0M | $1.9M | $6.8M | $5.3M | -$210.1K | $899.4K | $116.9K | $285.8K | $2.4M | $9.1M | -$14.7M | -$28.3K | ||||||||
| Operating Expenses | $17.3M | $21.6M | $16.8M | $23.1M | $17.2M | $18.0M | $17.0M | $20.8M | $37.8M | $27.2M | $30.6M | $1.9M | ||||||||
| Other Nonoperating Income Expense | -$3.0K | -$19.0K | -$142.0K | $529.0K | -$14.0K | -$601.0K | $128.0K | |||||||||||||
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -$44.0K | $302.0K | -$269.0K | -$230.0K | ||||||||||||||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | -$44.0K | $302.0K | -$269.0K | -$230.0K | ||||||||||||||||
| Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities | -$1.4M | $131.2K | $3.9M | -$2.3M | $3.8M | -$6.5M | $40.4M | $470.7K | ||||||||||||
| Net Income Loss Available To Common Stockholders Basic | -$9.6M | -$3.6M | -$4.3M | -$2.1M | ||||||||||||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$18.3M | -$19.8M | -$45.3M | -$1.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q1 2016 | Q3 2015 | Q2 2015 | Q1 2015 | Q3 2014 | Q2 2014 | Q1 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$6.4M | -$1.9M | -$3.7M | -$2.9M | -$7.6M | -$5.6M | -$2.9M | -$4.0M | $1.0M | $913.5K | -$7.4M | -$3.7M | -$2.9M | -$5.9M | -$186.5K | -$3.0M | -$48.7M | -$1.7M | -$1.7M | -$223.1K | -$2.2M | -$1.7M |
| Operating Income Loss | -$7.4M | -$3.1M | -$3.5M | -$2.9M | -$7.4M | -$6.0M | -$2.5M | -$4.6M | -$4.6M | -$246.9K | -$5.9M | -$4.9M | -$3.1M | -$6.0M | $12.0K | -$3.9M | -$23.3M | -$1.5M | -$1.7M | -$218.0K | -$2.3M | -$1.9M |
| Selling General And Administrative Expense | $2.0M | $2.5M | $2.7M | $1.7M | $2.2M | $3.7M | $2.8M | $3.1M | $2.9M | $1.8M | $2.9M | $2.2M | $1.4M | $2.4M | $2.3M | $2.4M | $2.7M | $1.3M | $99.7K | $55.5K | $790.0K | $1.1M |
| Research And Development Expense | $249.0K | $667.0K | $813.0K | $143.0K | $3.3M | $2.3M | -$314.0K | $1.5M | $1.7M | $1.5M | $1.3M | $142.0K | $1.6M | $162.6K | $1.5M | $800.0K | ||||||
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$38.0K | -$333.0K | -$35.0K | -$177.0K | $12.0K | $279.0K | -$3.0K | -$57.0K | $2.0K | -$3.7K | -$46.0K | -$222.7K | $3.3K | -$160.1K | $107.2K | -$192.9K | -$43.3K | $23.9K | -$20.4K | |||
| Comprehensive Income Net Of Tax | -$6.4M | -$2.2M | -$3.7M | -$3.1M | -$7.5M | -$5.3M | -$2.9M | -$4.1M | $1.0M | $909.8K | -$7.5M | -$4.0M | -$2.9M | -$6.1M | -$79.3K | -$3.2M | -$48.8M | -$1.7M | -$243.5K | |||
| Nonoperating Income Expense | -$84.0K | $1.2M | -$180.0K | $32.0K | -$109.0K | $423.0K | -$364.0K | $615.0K | $5.6M | $1.2M | -$1.5M | $1.2M | $235.4K | $83.7K | -$198.5K | $866.6K | -$25.4M | -$42.2K | -$5.1K | |||
| Operating Expenses | $3.5M | $6.0M | $246.9K | $5.9M | $4.9M | $3.1M | $6.0M | -$12.0K | $3.9M | $23.3M | $1.7M | $218.0K | ||||||||||
| Other Nonoperating Income Expense | -$2.0K | -$22.0K | -$13.0K | -$11.0K | -$215.0K | -$535.0K | $101.0K | $143.0K | ||||||||||||||
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -$38.0K | -$333.0K | -$35.0K | -$177.0K | $12.0K | $279.0K | -$3.0K | -$57.0K | $2.0K | |||||||||||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | -$333.0K | -$35.0K | -$177.0K | $12.0K | $279.0K | -$2.0K | -$57.0K | $2.0K | ||||||||||||||
| Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities | -$4.0M | $415.5K | -$4.5M | -$291.7K | ||||||||||||||||||
| Net Income Loss Available To Common Stockholders Basic | ||||||||||||||||||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$7.5M | -$2.9M | -$3.0M | -$48.7M | -$1.7M | -$1.7M | -$223.1K | -$2.2M | -$1.7M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $28.3M | $22.2M | -$229.0K | $1.8M | $5.6M | $9.4M | $7.6K | $4.4M | $22.2M | $34.1M | $48.7M | $2.2M | $400.7K | -$3.4M | -$2.5M | -$2.0M | -$1.7M | -$1.3M | -$60.0K | -$467.0K | $1.2M | $0.00 |
| Cash And Cash Equivalents At Carrying Value | $3.8M | $13.3M | $9.4M | $14.1M | $5.7M | $5.4M | $28.1M | $34.1M | $68.9M | $3.3M | $553.7K | $1.1M | $6.0K | $9.0K | $0.00 | |||||||
| Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss | $775.0K | $2.1M | $6.6M | $6.9M | $0.00 | $556.8K | $198.9K | $0.00 | $2.6M | $8.7M | $11.4M | $0.00 | ||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $5.3M | $2.7M | $3.8M | $13.3M | $9.4M | $14.1M | $5.7M | $6.0M | $28.2M | $34.2M | $69.1M | |||||||||||
| Retained Earnings Accumulated Deficit | -$264.6M | -$247.3M | -$227.5M | -$217.5M | -$199.7M | -$182.3M | -$165.2M | -$126.8M | -$110.3M | -$74.9M | -$56.8M | -$11.5M | -$20.5M | -$16.9M | ||||||||
| Liabilities And Stockholders Equity | $47.9M | $50.6M | $4.4M | $13.8M | $11.6M | $14.6M | $6.5M | $8.0M | $29.1M | $45.9M | $69.9M | $3.4M | $7.8M | $1.1M | ||||||||
| Assets Current | $5.5M | $3.0M | $4.3M | $13.8M | $11.6M | $14.6M | $6.4M | $7.5M | $28.8M | $45.6M | $69.7M | $3.3M | $7.8M | $1.1M | ||||||||
| Assets | $47.9M | $50.6M | $4.4M | $13.8M | $11.6M | $14.6M | $6.5M | $8.0M | $29.1M | $45.9M | $69.9M | $3.4M | $7.8M | $1.1M | ||||||||
| Common Stock Value | $5.3M | $1.3M | $745.0K | $476.0K | $384.7K | $32.0M | $23.7M | $22.9M | $18.3M | $18.3M | $11.2M | $675.0K | $245.0K | |||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$782.0K | -$738.0K | -$1.0M | -$771.0K | -$541.0K | -$648.1K | -$348.9K | -$352.4K | -$236.2K | -$280.1K | $156.5K | $46.1K | -$33.4K | |||||||||
| Additional Paid In Capital Common Stock | $174.8M | $167.1M | $153.1M | $139.7M | $133.6M | $106.6M | $104.8M | $91.0M | $87.0M | $2.4M | $25.7M | $13.2M | ||||||||||
| Accrued Liabilities Current | $2.3M | $3.1M | $1.6M | $3.1M | $3.2M | $1.8M | $4.2M | $1.5M | $4.8M | $1.8M | $408.2K | $43.0K | ||||||||||
| Accounts Payable Current | $8.8M | $12.4M | $1.7M | $947.0K | $1.8M | $3.4M | $1.2M | $1.6M | $2.0M | $2.2M | $4.3M | $555.5K | ||||||||||
| Liabilities | $19.6M | $28.3M | $4.6M | $12.0M | $6.1M | $5.2M | $6.5M | $4.9M | $11.9M | $11.8M | $21.2M | $1.2M | ||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $2.6M | -$1.2M | -$9.4M | $3.9M | -$4.7M | $8.3M | -$236.3K | -$22.3M | -$6.0M | -$34.8M | ||||||||||||
| Liabilities Current | $12.4M | $19.9M | $4.6M | $4.9M | $11.8M | $11.7M | $21.1M | $1.2M | $1.2M | $3.9M | ||||||||||||
| Intangible Assets Net Excluding Goodwill | $14.0K | $17.0K | $22.9K | $27.2K | $30.2K | $33.0K | $39.1K | $39.4K | $52.5K | $59.4K | ||||||||||||
| Cash And Cash Equivalents Period Increase Decrease | -$6.0M | -$34.8M | $65.6M | $2.8M | $6.6M | $1.1M | -$3.0K | |||||||||||||||
| Property Plant And Equipment Net | $0.00 | $5.0K | $20.4K | $55.9K | $58.4K | $40.5K | $0.00 | $0.00 | $2.0K | |||||||||||||
| Liability Related To Stock Options And Warrants | $0.00 | $1.0M | $1.8M | $5.1M | $7.7M | $16.4M | $0.00 | $787.0K | $630.0K | |||||||||||||
| Other Assets Current | $14.0K | $201.0K | $197.0K | $100.0K | $90.3K | $229.2K | ||||||||||||||||
| Liabilities Noncurrent | $0.00 | $48.0K | $56.4K | $49.1K | $0.00 | $787.0K | $630.0K | |||||||||||||||
| Prepaid Expense And Other Assets Current | $521.9K | $713.0K | $1.4M | $706.4K | $1.5M | $728.1K | $7.8K | |||||||||||||||
| Warrant Liabilities Current | $61.0K | $1.0M | $1.3M | $7.9M | $0.00 | |||||||||||||||||
| Other Liabilities Current | $424.0K | $94.0K | $94.0K | $94.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q1 2019 | Q1 2016 | Q3 2015 | Q2 2015 | Q1 2015 | Q3 2014 | Q2 2014 | Q1 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $22.7M | $25.6M | $21.7M | -$6.7M | -$3.7M | -$3.6M | $213.0K | $2.8M | $6.6M | $46.4M | $41.3M | $973.0K | $2.6M | $10.4M | ||||||||
| Cash And Cash Equivalents At Carrying Value | $2.7M | $2.6M | $2.6M | $2.2M | $4.2M | $1.3M | $61.4M | $78.8M | $2.7M | $1.3M | $52.6K | $11.4M | $13.8M | |||||||||
| Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss | $253.0K | $134.0K | -$54.0K | $30.0K | -$151.0K | $649.0K | -$258.0K | $560.0K | $5.6M | $1.0M | -$1.6M | $949.5K | $198.9K | $0.00 | $704.3K | $638.7K | $0.00 | $0.00 | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $2.5M | $2.8M | $2.6M | $2.2M | $4.2M | $1.3M | $4.7M | $7.2M | $11.6M | |||||||||||||
| Retained Earnings Accumulated Deficit | -$259.3M | -$252.9M | -$251.0M | -$243.5M | -$240.6M | -$233.0M | -$59.8M | -$63.3M | -$34.2M | -$32.5M | ||||||||||||
| Liabilities And Stockholders Equity | $45.4M | $50.9M | $51.0M | $2.7M | $5.1M | $2.8M | $63.0M | $79.2M | $3.0M | $4.3M | ||||||||||||
| Assets Current | $2.9M | $3.3M | $3.3M | $2.7M | $5.1M | $2.8M | $62.7M | $78.9M | $2.9M | $4.3M | ||||||||||||
| Assets | $45.4M | $50.9M | $51.0M | $2.7M | $5.1M | $2.8M | $63.0M | $79.2M | $3.0M | $4.3M | ||||||||||||
| Common Stock Value | $6.5M | $6.5M | $5.8M | $2.4M | $2.4M | $1.6M | $18.3M | $18.3M | $927.0K | $927.0K | ||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$1.1M | -$1.1M | -$773.0K | -$926.0K | -$749.0K | -$761.0K | -$36.5K | $197.1K | ||||||||||||||
| Additional Paid In Capital Common Stock | $215.5M | $212.7M | $183.1M | $183.0M | $176.4M | $87.8M | $86.1M | $34.2M | $34.2M | |||||||||||||
| Accrued Liabilities Current | $1.6M | $2.5M | $3.5M | $2.6M | $1.7M | $1.5M | $231.9K | $3.8M | ||||||||||||||
| Accounts Payable Current | $10.8M | $11.6M | $13.1M | $4.8M | $4.7M | $3.2M | $625.4K | $3.8M | ||||||||||||||
| Liabilities | $22.7M | $25.3M | $29.2M | $16.6M | $37.8M | |||||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$17.0K | -$2.5M | -$1.7M | $2.1M | $325.5K | |||||||||||||||||
| Liabilities Current | $15.6M | $17.1M | $20.9M | $9.4M | $8.8M | $6.3M | $16.5M | $37.8M | $960.0K | $910.0K | ||||||||||||
| Intangible Assets Net Excluding Goodwill | $49.0K | $58.1K | ||||||||||||||||||||
| Cash And Cash Equivalents Period Increase Decrease | -$7.5M | -$2.0M | $6.2M | |||||||||||||||||||
| Property Plant And Equipment Net | $74.8K | $34.9K | $40.0K | $44.0K | ||||||||||||||||||
| Liability Related To Stock Options And Warrants | $15.7M | $27.2M | $984.0K | $774.0K | ||||||||||||||||||
| Other Assets Current | $53.0K | $83.0K | $80.0K | $92.0K | $94.0K | $232.0K | ||||||||||||||||
| Liabilities Noncurrent | $52.1K | $46.0K | $1.0M | $812.0K | ||||||||||||||||||
| Prepaid Expense And Other Assets Current | $1.3M | |||||||||||||||||||||
| Warrant Liabilities Current | $503.0K | $866.0K | $1.1M | $725.0K | $755.0K | $604.0K | ||||||||||||||||
| Other Liabilities Current | $481.0K | $650.0K | $484.0K | $316.0K | $653.0K | $983.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financing Cash Flow * | $13.2M | $11.0M | $7.0M | $25.3M | $14.3M | $25.1M | $12.6M | $500.0K | $15.7M | $0.00 | $69.0M | $4.2M | $12.0M | $3.2M | $1.0M | |||||
| Investing Cash Flow * | $382.0K | $0.00 | $0.00 | $10.0M | -$10.1M | $1.4M | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||
| Operating Cash Flow * | -$10.6M | -$12.6M | -$16.4M | -$21.5M | -$18.8M | -$17.0M | -$12.9M | -$22.8M | -$31.6M | -$24.6M | -$5.0M | -$1.5M | -$5.5M | -$2.1M | -$1.0M | |||||
| Proceeds From Issuance Of Common Stock | $10.7M | $11.8M | $7.0M | $25.2M | $14.3M | $25.0M | $12.6M | $500.0K | $15.7M | $0.00 | $75.0M | $3.7M | $0.00 | $118.0K | $75.0K | $7.6M | ||||
| Share Based Compensation | $2.9M | $2.2M | $1.2M | $735.0K | $314.7K | $325.5K | $1.0M | $1.6M | $2.7M | $3.9M | $1.0M | $0.00 | $94.0K | $514.0K | $140.0K | |||||
| Increase Decrease In Accounts Receivables And Prepaid Expense | -$1.3M | -$70.0K | -$1.7M | $1.7M | -$192.1K | -$710.3K | $716.9K | -$807.4K | $785.9K | -$913.8K | $8.4K | $161.0K | -$7.0K | -$4.0K | ||||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$998.0K | $5.2M | -$936.0K | -$877.0K | -$241.3K | -$247.7K | $2.4M | -$3.7M | $12.2K | -$671.8K | $3.8M | $474.2K | ||||||||
| Depreciation Depletion And Amortization | $14.0K | $4.0K | $4.0K | $4.1K | $8.9K | $19.2K | $35.8K | $42.4K | $39.9K | $10.2K | $4.9K | |||||||||
| Payments To Acquire Property Plant And Equipment | $0.00 | $0.00 | $36.9K | $54.8K | $10.6K | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||
| Stock Issued During Period Value Share Based Compensation | $94.0K | $450.0K | $140.0K | $70.0K | $168.0K | $448.0K | $69.0K | |||||||||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $1.0K | -$4.0K | $7.0K | $105.0K | -$140.7K | $200.5K | $34.1K | -$6.9K | -$50.3K | -$129.9K | ||||||||||
| Proceeds From Convertible Debt | $1.0M | $0.00 | $0.00 | $890.0K | $0.00 | |||||||||||||||
| Proceeds From Issuance Of Warrants | $1.0M | $8.2M | $13.1M | $2.2M | $930.0K | |||||||||||||||
| Increase Decrease In Values Of Deferred Shares And Liability Related To Stock Options And Warrants | 552.0K | 286.0K | 418.0K | 120.0K | ||||||||||||||||
| Increase Decrease In Other Accounts Payable | -$223.0K | -$676.0K | $394.0K | $475.0K | ||||||||||||||||
| Increase Decrease In Accounts Payable Trade | $351.0K | -$1.0M | $627.0K | $612.0K | ||||||||||||||||
| Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations | -$140.7K | $200.5K | $34.1K | -$6.9K | -$50.4K | -$130.0K | $121.9K | $15.3K | ||||||||||||
| Increase Decrease In Accrued Liabilities | $0.00 | $242.0K | $1.0M | $0.00 | ||||||||||||||||
| Increase Decrease In Other Operating Liabilities | $0.00 | $0.00 | -$48.0K | -$8.4K | $7.3K | $3.5K | $0.00 | |||||||||||||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans | 33.0K | 2.0K | 4.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q2 2025 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2020 | Q1 2019 | Q1 2016 | Q1 2015 | Q1 2014 | Q2 2012 | Q1 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Financing Cash Flow * | $2.1M | $1.5M | $3.2M | $9.9M | $157.7K | $0.00 | $8.2M | ||||
| Investing Cash Flow * | -$42.1K | $0.00 | $0.00 | ||||||||
| Operating Cash Flow * | -$2.2M | -$4.0M | -$4.9M | -$7.7M | $228.9K | -$7.4M | -$2.0M | -$2.0M | |||
| Proceeds From Issuance Of Common Stock | $1.6M | $1.7M | $3.2M | $7.1M | $157.7K | ||||||
| Share Based Compensation | $1.0M | $296.0K | $265.0K | $100.5K | $394.4K | $816.8K | $0.00 | $195.0K | $2.0K | ||
| Increase Decrease In Accounts Receivables And Prepaid Expense | -$84.0K | -$138.0K | $239.0K | $1.1M | $464.7K | $524.1K | $10.0K | $160.0K | |||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $483.0K | $1.5M | -$324.0K | -$1.9M | $313.6K | -$3.9M | -$282.4K | ||||
| Depreciation Depletion And Amortization | $13.0K | $1.0K | $3.9K | $5.6K | |||||||
| Payments To Acquire Property Plant And Equipment | $42.1K | $0.00 | |||||||||
| Stock Issued During Period Value Share Based Compensation | $33.0K | $3.0K | $59.0K | $2.0K | |||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$5.0K | ||||||||||
| Proceeds From Convertible Debt | $1.1M | ||||||||||
| Proceeds From Issuance Of Warrants | $0.00 | $8.2M | |||||||||
| Increase Decrease In Values Of Deferred Shares And Liability Related To Stock Options And Warrants | -539.0K | 151.0K | |||||||||
| Increase Decrease In Other Accounts Payable | $258.0K | -$384.0K | |||||||||
| Increase Decrease In Accounts Payable Trade | -$707.0K | $192.0K | |||||||||
| Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations | -$47.8K | -$61.2K | -$7.8K | -$10.3K | |||||||
| Increase Decrease In Accrued Liabilities | |||||||||||
| Increase Decrease In Other Operating Liabilities | $3.0K | $0.00 | |||||||||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans | 3.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2008 | FY2007 | FY2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.03 | -$0.02 | -$0.05 | -$0.02 | -$0.17 | -$0.35 | -$0.18 | ||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | |||
| Common Stock Shares Authorized | 761.96B | 245.04B | 45.12B | 15.00B | 15.00B | 15.00B | 10.00B | 10.00B | 5.00B | 5.00B | 5.00B | 5.00B | 5.00B | 49.8M | |||||
| Common Stock Shares Outstanding | 90.54B | 53.19B | 13.23B | 7.44B | 4.76B | 3.85B | 2.25B | 312.0K | 1.53B | 1.18B | 1.18B | 722.3M | 40.2M | 13.4M | |||||
| Common Stock Shares Issued | 90.54B | 53.19B | 13.23B | 7.44B | 4.76B | 4.76B | 2.25B | 1.58B | 1.53B | 1.18B | 1.18B | 722.3M | 40.2M | 40.2M | |||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 3.16B | 1.83B | 1.54B | 1.25B | 1.18B | 852.1M | 85.5M | 21.1M | 12.5M | 11.9M | |||||||||
| Weighted Average Number Of Shares Outstanding Basic | 67.33B | 23.89B | 9.79B | 6.24B | 4.29B | 3.16B | 1.83B | 54.1M | 21.1M | 12.5M | |||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 67.33B | 23.89B | 9.79B | 6.24B | 4.29B | 3.16B | 1.83B | 54.3M | 21.1M | 12.5M | |||||||||
| Earnings Per Share Basic | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $-0.01 | ||||||||||||
| Equity Issuance Per Share Amount | $0.57 | $2.00 | $1.58 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q1 2016 | Q3 2015 | Q2 2015 | Q1 2015 | Q3 2014 | Q2 2014 | Q1 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$0.00 | -$0.06 | -$0.03 | -$0.00 | $0.00 | -$0.04 | -$0.04 | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | |||||||||
| Common Stock Shares Authorized | 330.85B | 330.85B | 245.04B | 45.12B | 45.12B | 45.12B | 35.00B | 35.00B | 5.00B | 5.00B | 5.00B | 5.00B | |||||||||||
| Common Stock Shares Outstanding | 65.23B | 65.23B | 57.75B | 24.29B | 24.29B | 15.97B | 1.18B | 1.18B | 55.6M | 55.6M | |||||||||||||
| Common Stock Shares Issued | 65.23B | 65.23B | 57.75B | 24.29B | 24.29B | 15.97B | 1.18B | 1.18B | 55.6M | 55.6M | |||||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 3.39B | 3.00B | 2.52B | 1.97B | 1.61B | 1.58B | 1.18B | 781.7M | 55.6M | 722.3M | 73.4M | 55.6M | 49.5M | ||||||||||
| Weighted Average Number Of Shares Outstanding Basic | 65.33B | 62.94B | 54.59B | 24.39B | 18.84B | 13.45B | 10.12B | 10.12B | 7.47B | ||||||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 65.33B | 62.94B | 54.59B | 24.39B | 18.84B | 13.45B | 10.12B | 10.12B | 7.57B | ||||||||||||||
| Earnings Per Share Basic | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||||
| Equity Issuance Per Share Amount | $2.00 | $0.60 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value New Issues | $11.7M | $11.5M | $7.0M | $13.5M | $13.2M | $22.3M | $11.4M | $1.1M | $15.7M | $69.6M | $8.2M | $11.6M | $1.9M | $930.0K | $312.0K | $499.0K | $69.0K | $3.1M | |
| Investment Income Interest | $1.0K | $8.0K | $82.0K | $46.0K | $10.6K | $13.6K | $5.5K | $222.3K | $175.4K | $143.2K | $20.7K | $91.00 | |||||||
| Foreign Currency Transaction Gain Loss Realized | -$443.0K | $6.0K | $136.0K | $453.0K | -$193.2K | $350.9K | -$67.3K | $81.5K | -$358.5K | $273.0K | -$90.6K | ||||||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.9M | $2.2M | $1.2M | $735.0K | $314.7K | $325.5K | $1.0M | $1.6M | $2.7M | $3.9M | $1.0M | ||||||||
| Foreign Currency Transaction Gain Loss Before Tax | $99.0K | -$255.0K | $255.0K | $334.0K | -$242.5K | $490.8K | $30.4K | $104.7K | -$93.4K | $273.0K | $0.00 | -$22.9K | |||||||
| Taxes Other | $141.5K | $27.5K | $22.0K | $20.3K | $17.9K | $13.4K | $44.0K | $44.2K | $0.00 | ||||||||||
| Capital Redemption Reserve | $59.3M | $52.2M | $52.2M | $52.2M | $52.2M | $0.00 | |||||||||||||
| Depreciation | $10.2K | $4.9K | $2.0K | $2.0K | $0.00 | ||||||||||||||
| Stock Issued During Period Shares New Issues | 348.0M | 751.5K | 11.6M | ||||||||||||||||
| Prepaid Expense Current | $185.0K | $92.0K | $299.0K | $465.0K | $2.2M | $292.7K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q1 2016 | Q3 2015 | Q1 2015 | Q3 2014 | Q1 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value New Issues | $4.4M | $2.2M | $7.0M | $1.7M | $3.5M | ||||||||||||||||
| Investment Income Interest | $1.0K | $3.0K | $2.0K | $2.0K | $16.0K | $29.0K | $30.0K | $6.1K | $1.2K | $1.0K | $2.1K | $449.00 | $1.3K | $30.8K | $1.4K | $0.00 | $0.00 | ||||
| Foreign Currency Transaction Gain Loss Realized | $76.0K | -$50.0K | -$125.0K | $68.0K | $91.0K | -$226.0K | -$100.0K | $39.0K | -$11.0K | $156.4K | $28.0K | $233.4K | $37.2K | $86.4K | -$195.6K | ||||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $685.0K | $719.0K | $1.0M | $248.0K | $445.0K | $296.0K | $305.0K | $276.0K | $265.0K | $816.8K | |||||||||||
| Foreign Currency Transaction Gain Loss Before Tax | $27.0K | -$264.0K | -$3.0K | $171.8K | -$166.6K | $154.4K | -$22.00 | -$37.6K | -$2.2K | ||||||||||||
| Taxes Other | $5.7K | $1.7K | $2.3K | $2.8K | $3.2K | $4.1K | $23.0K | $21.4K | $0.00 | $0.00 | |||||||||||
| Capital Redemption Reserve | $52.2M | $52.2M | $52.2M | $52.2M | $52.2M | $52.2M | $50.6M | ||||||||||||||
| Depreciation | $8.6K | $764.00 | $0.00 | ||||||||||||||||||
| Stock Issued During Period Shares New Issues | 15.3M | ||||||||||||||||||||
| Prepaid Expense Current | $349.0K | $447.0K | $627.0K | $396.0K | $805.0K | $1.2M |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.